{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T11:32:09Z","timestamp":1771068729777,"version":"3.50.1"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673617"],"award-info":[{"award-number":["81673617"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ejphar.2024.177074","type":"journal-article","created":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T22:16:41Z","timestamp":1730326601000},"page":"177074","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Integrated metabolomics and network pharmacology analysis to reveal the protective effect of Complanatoside A on nonalcoholic fatty liver disease"],"prefix":"10.1016","volume":"985","author":[{"given":"Sijia","family":"Jiang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoxu","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Hua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangqiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingtong","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danyue","family":"Shao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yiwei","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuehua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxia","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejphar.2024.177074_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103751","article-title":"Metabolomics and lipidomics strategies in modern drug discovery and development","volume":"28","author":"Astarita","year":"2023","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejphar.2024.177074_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202400493","article-title":"Lipid nanoparticle-mediated delivery of CRISPR-cas9 against rubicon ameliorates NAFLD by modulating CD36 along with glycerophospholipid metabolism","author":"Bai","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ejphar.2024.177074_bib49","series-title":"Pharmacopoeia of the People\u2019s Republic of China","year":"2020"},{"issue":"4","key":"10.1016\/j.ejphar.2024.177074_bib4","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \"hits\"","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ejphar.2024.177074_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.880298","article-title":"Association of inflammatory cytokines with non-alcoholic fatty liver disease","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.ejphar.2024.177074_bib6","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.26338","article-title":"Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications","volume":"58","author":"Garcia-Martinez","year":"2013","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.ejphar.2024.177074_bib7","first-page":"116","article-title":"Clinical application of metabolomics in pancreatic diseases: a mini-review","volume":"51","author":"Gu","year":"2020","journal-title":"Lab. Med."},{"issue":"6","key":"10.1016\/j.ejphar.2024.177074_bib8","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.biotechadv.2018.03.003","article-title":"Natural products as modulators of the nuclear receptors and metabolic sensors LXR, FXR and RXR","volume":"36","author":"Hiebl","year":"2018","journal-title":"Biotechnol. Adv."},{"issue":"5","key":"10.1016\/j.ejphar.2024.177074_bib9","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/hep.20170","article-title":"Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice","volume":"39","author":"Ip","year":"2004","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.ejphar.2024.177074_bib10","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.3390\/ijms20051149","article-title":"An updated review of lysophosphatidylcholine metabolism in human diseases","volume":"20","author":"Law","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ejphar.2024.177074_bib11","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.cyto.2012.10.007","article-title":"Tumour necrosis factor alpha down-regulates the expression of peroxisome proliferator activated receptor alpha (PPAR\u03b1) in human hepatocarcinoma HepG2 cells by activation of NF-\u03baB pathway","volume":"61","author":"Lim","year":"2013","journal-title":"Cytokine"},{"key":"10.1016\/j.ejphar.2024.177074_bib48","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-981-10-8684-7_2","article-title":"Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC","volume":"1061","author":"Liu","year":"2018","journal-title":"Adv Exp Med Biol"},{"issue":"10","key":"10.1016\/j.ejphar.2024.177074_bib13","first-page":"1044","article-title":"Effect of Complanatoside A on TG transport pathway regulated by HNF4\u03b1 in steatotic L02 cells","volume":"45","author":"Liu","year":"2022","journal-title":"J Beij Uni Tra Chin Med"},{"key":"10.1016\/j.ejphar.2024.177074_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2021.113949","article-title":"The synergistic anti-depression effects of different efficacy groups of Xiaoyaosan as demonstrated by the integration of network pharmacology and serum metabolomics","volume":"197","author":"Liu","year":"2021","journal-title":"J Pharmaceut Biomed"},{"issue":"11","key":"10.1016\/j.ejphar.2024.177074_bib15","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1093\/nutrit\/nuy031","article-title":"Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"76","author":"Loman","year":"2018","journal-title":"Nutr. Rev."},{"issue":"7","key":"10.1016\/j.ejphar.2024.177074_bib16","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPAR\u03b1 is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.ejphar.2024.177074_bib17","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1038\/s41569-021-00569-6","article-title":"PPAR control of metabolism and cardiovascular functions","volume":"18","author":"Montaigne","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"issue":"6","key":"10.1016\/j.ejphar.2024.177074_bib18","doi-asserted-by":"crossref","first-page":"824","DOI":"10.3390\/biom12060824","article-title":"NAFLD: mechanisms, treatments, and biomarkers","volume":"12","author":"Nassir","year":"2022","journal-title":"Biomolecules"},{"issue":"1","key":"10.1016\/j.ejphar.2024.177074_bib19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jhep.2022.08.022","article-title":"IL-6\/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease","volume":"78","author":"Park","year":"2023","journal-title":"J. Hepatol."},{"issue":"6","key":"10.1016\/j.ejphar.2024.177074_bib20","article-title":"New targets for NAFLD","volume":"3","author":"Parlati","year":"2021","journal-title":"JHEP Rep"},{"issue":"2","key":"10.1016\/j.ejphar.2024.177074_bib21","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1124\/jpet.119.256792","article-title":"Withaferin a improves nonalcoholic steatohepatitis in mice","volume":"371","author":"Patel","year":"2019","journal-title":"Journal Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.ejphar.2024.177074_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhepr.2022.100479","article-title":"Lipid alterations in chronic liver disease and liver cancer","volume":"4","author":"Paul","year":"2022","journal-title":"JHEP reports : innovation in hepatology"},{"issue":"3","key":"10.1016\/j.ejphar.2024.177074_bib23","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","article-title":"Molecular mechanism of PPAR\u03b1 action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease","volume":"62","author":"Pawlak","year":"2015","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.ejphar.2024.177074_bib47","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.ymthe.2019.06.017","article-title":"A Mitochondrial VDAC1-Based Peptide Greatly Suppresses Steatosis and NASH-Associated Pathologies in a Mouse Model","volume":"27","author":"Pittala","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.ejphar.2024.177074_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106786","article-title":"Roles of the peroxisome proliferator-activated receptors (PPARs) in the pathogenesis of nonalcoholic fatty liver disease (NAFLD)","volume":"192","author":"Qiu","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"12","key":"10.1016\/j.ejphar.2024.177074_bib25","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/jama.2020.2298","article-title":"Nonalcoholic steatohepatitis: a review","volume":"323","author":"Sheka","year":"2020","journal-title":"JAMA"},{"issue":"17","key":"10.1016\/j.ejphar.2024.177074_bib26","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241713137","article-title":"Osteoarthritis: role of peroxisome proliferator-activated receptors","volume":"24","author":"Sheng","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.177074_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105484","article-title":"Epigenetics in NAFLD\/NASH: targets and therapy","volume":"167","author":"Sodum","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"11","key":"10.1016\/j.ejphar.2024.177074_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0224405","article-title":"Tributyltin chloride (TBT) induces RXRA down-regulation and lipid accumulation in human liver cells","volume":"14","author":"Stossi","year":"2019","journal-title":"PloS one"},{"issue":"7\u20138","key":"10.1016\/j.ejphar.2024.177074_bib28","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1080\/07853890.2019.1693056","article-title":"Impaired albumin function: a novel potential indicator for liver function damage?","volume":"51","author":"Sun","year":"2019","journal-title":"Ann. Med."},{"issue":"8","key":"10.1016\/j.ejphar.2024.177074_bib29","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3390\/biom10081133","article-title":"Arachidonic acid as an early indicator of inflammation during non-alcoholic fatty liver disease development","volume":"10","author":"Sztolsztener","year":"2020","journal-title":"Biomolecules"},{"issue":"7","key":"10.1016\/j.ejphar.2024.177074_bib30","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.ejphar.2024.177074_bib31","doi-asserted-by":"crossref","first-page":"792","DOI":"10.3390\/biology11050792","article-title":"PPAR alpha as a metabolic modulator of the liver: role in the pathogenesis of nonalcoholic steatohepatitis (NASH)","volume":"11","author":"Todisco","year":"2022","journal-title":"Biology"},{"issue":"2","key":"10.1016\/j.ejphar.2024.177074_bib32","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S2468-1253(23)00275-3","article-title":"Hepatocellular and extrahepatic cancer risk in people with non-alcoholic fatty liver disease","volume":"9","author":"Thomas","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.ejphar.2024.177074_bib33","first-page":"13","article-title":"Oxidized phospholipids and lipoprotein-associated phospholipase A2 as important determinants of Lp(a) functionality and pathophysiological role","volume":"31","author":"Tselepis","year":"2018","journal-title":"J Biom Res"},{"issue":"9 Pt B","key":"10.1016\/j.ejphar.2024.177074_bib34","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.bbamem.2017.04.006","article-title":"The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease","volume":"1859","author":"van der Veen","year":"2017","journal-title":"BBA-Biomembranes"},{"key":"10.1016\/j.ejphar.2024.177074_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113075","article-title":"Corynoline protects ang II-induced hypertensive heart failure by increasing PPAR\u03b1 and Inhibiting NF-\u03baB pathway","volume":"150","author":"Wang","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"15","key":"10.1016\/j.ejphar.2024.177074_bib36","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.3390\/ijms20153683","article-title":"Arachidonic acid metabolism and kidney inflammation","volume":"20","author":"Wang","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.177074_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2020.113196","article-title":"Serum metabonomics coupled with HPLC-LTQ\/orbitrap MS and multivariate data analysis on the ameliorative effects of Bidens bipinnata L. in hyperlipidemic rats","volume":"262","author":"Wang","year":"2020","journal-title":"J. Ethnopharmacol."},{"issue":"2","key":"10.1016\/j.ejphar.2024.177074_bib38","doi-asserted-by":"crossref","first-page":"24","DOI":"10.3892\/mmr.2023.13147","article-title":"Albumin, an interesting and functionally diverse protein, varies from 'native' to 'effective'","volume":"29","author":"Wu","year":"2024","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejphar.2024.177074_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103707","article-title":"Multi-stage metabolomics and genetic analyses identified metabolite biomarkers of metabolic syndrome and their genetic determinants","volume":"74","author":"Wu","year":"2021","journal-title":"EBioMedicine"},{"issue":"8","key":"10.1016\/j.ejphar.2024.177074_bib40","doi-asserted-by":"crossref","first-page":"4714","DOI":"10.1039\/D1FO04386B","article-title":"Network pharmacology combined with metabolomics and lipidomics to reveal the hypolipidemic mechanism of Alismatis rhizoma in hyperlipidemic mice","volume":"13","author":"Yan","year":"2022","journal-title":"Food Funct."},{"issue":"8","key":"10.1016\/j.ejphar.2024.177074_bib41","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.3390\/ijms21082790","article-title":"Sweroside prevents non-alcoholic steatohepatitis by suppressing activation of the NLRP3 inflammasome","volume":"21","author":"Yang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejphar.2024.177074_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2020.120710","article-title":"Integrated strategy for accurately screening biomarkers based on metabolomics coupled with network pharmacology","volume":"211","author":"Zhang","year":"2020","journal-title":"Talanta"},{"issue":"624","key":"10.1016\/j.ejphar.2024.177074_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abg8117","article-title":"Multiple omics study identifies an interspecies conserved driver for nonalcoholic steatohepatitis","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejphar.2024.177074_bib43","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/4202563","article-title":"Network pharmacology analysis of traditional Chinese medicine formula Xiao Ke Yin Shui treating type 2 diabetes mellitus","author":"Zhou","year":"2019","journal-title":"Evid-Based Compl Alt"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924007647?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299924007647?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,8]],"date-time":"2024-12-08T01:28:09Z","timestamp":1733621289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299924007647"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":46,"alternative-id":["S0014299924007647"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.177074","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integrated metabolomics and network pharmacology analysis to reveal the protective effect of Complanatoside A on nonalcoholic fatty liver disease","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2024.177074","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"177074"}}